Views of Wall Street’s Leading Experts on 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc. (NASDAQ: FDMT) stock fell -1.33% on Friday to $15.56 against a previous-day closing price of $15.77. With 1.36 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.34 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $15.86 whereas the lowest price it dropped to was $15.45. The 52-week range on FDMT shows that it touched its highest point at $26.49 and its lowest point at $6.58 during that stretch. It currently has a 1-year price target of $35.14. Beta for the stock currently stands at 2.36.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of FDMT was down-trending over the past week, with a drop of -0.70%, but this was down by -2.38% over a month. Three-month performance dropped to -25.90% while six-month performance fell -15.25%. The stock gained 66.06% in the past year, while it has lost -29.94% so far this year. A look at the trailing 12-month EPS for FDMT yields -3.29 with Next year EPS estimates of -3.25. For the next quarter, that number is -0.54. This implies an EPS growth rate of -29.20% for this year and -13.70% for next year. EPS is expected to decline by -9.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -9.30%.

Float and Shares Shorts:

At present, 42.05 million FDMT shares are outstanding with a float of 39.40 million shares on hand for trading. On Aug 30, 2023, short shares totaled 3.57 million, which was 8.48% higher than short shares on Jul 30, 2023. In addition to FDHT as the firm’s FDHT, FDMT serves as its 4D Molecular Therapeutics, Inc.

Institutional Ownership:

Through their ownership of 90.78% of FDMT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 64.73% of FDMT, in contrast to 25.53% held by mutual funds. Shares owned by individuals account for 18.60%. As the largest shareholder in FDMT with 11.39% of the stake, Viking Global Investors LP holds 4,787,914 shares worth 4,787,914. A second-largest stockholder of FDMT, BVF Partners LP, holds 4,007,413 shares, controlling over 9.53% of the firm’s shares. RA Capital Management LP is the third largest shareholder in FDMT, holding 3,069,531 shares or 7.30% stake. With a 3.26% stake in FDMT, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 1,368,762 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.71% of FDMT stock, is the second-largest Mutual Fund holder. It holds 1,139,344 shares valued at 18.55 million. Janus Henderson Global Life Scien holds 2.17% of the stake in FDMT, owning 914,430 shares worth 14.89 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, FDMT reported revenue of $162.00k and operating income of -$28.43M. The EBITDA in the recently reported quarter was -$27.59M and diluted EPS was -$0.87.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for FDMT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With FDMT analysts setting a high price target of $50.00 and a low target of $22.00, the average target price over the next 12 months is $35.14. Based on these targets, FDMT could surge 221.34% to reach the target high and rise by 41.39% to reach the target low. Reaching the average price target will result in a growth of 125.84% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded FDMT stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 11 while that of sell transactions has risen to 24 over the past year. The total number of shares bought during that period was 1,477,875 while 763,842 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *